(Q45949258)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Improving outcomes for patients with chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Robert G Gish

series ordinal

1

1 reference

18 December 2017

http://europepmc.org/abstract/MED/17627639

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

s1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

S67-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Epidemiology and prevention of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Chronic hepatitis B: current epidemiology in the Americas and implications for management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Treatment options in HBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Determinants for sustained HBeAg response to lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Genomic analysis of the host response to hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Vaccination against hepatitis B: current challenges for Asian countries and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Viral dynamics in chronic hepatitis B patients during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00108.X

10.1111/J.1872-034X.2007.00108.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627639%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference